CTOs on the Move

Central Wyoming Counseling Center

www.cwcc.us

 
Central Wyoming Counseling Center is a non-profit Community Mental Health and Substance Abuse Treatment Center that is dedicated to helping Residents of Wyoming.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.cwcc.us
  • 1430, Wilkins Circle
    Casper, WY USA 82601
  • Phone: 307.237.9583

Executives

Name Title Contact Details

Similar Companies

video king inc

video king inc is a Elkton, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AbbVie

At AbbVie, we believe the world needs new approaches to addressing today`s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people`s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people`s lives.

KP Consulting

KP Consulting Inc. is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fluid Air

Fluid Air, Inc. is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.